Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Janssen,Ibrutinib,"Chronic lymphocytic leukemia (CLL), previously untreated, chemoimmunotherapy is inappropriate (BTKi class recommendation received)",Ibrutinib (Imbruvica),Recommended for decline,,Oncology Agents and Immunosuppressants
